Zardaverine

Zardaverine
Names
	Preferred IUPAC name 6-[3-(Difluoromethoxy)-4-methoxyphenyl]pyridazin-3(2H)-one
Identifiers
CAS Number	101975-10-4 ;
3D model (JSmol)	Interactive image;
ChemSpider	5521;
PubChem CID	5723;
UNII	TQ358GWH6Y ;
CompTox Dashboard (EPA)	DTXSID8042559 ;
	InChI InChI=1S/C12H10F2N2O3/c1-18-10-6-7(2-4-9(10)19-12(13)14)8-3-5-11(17)16-15-8/h2-6,12H,1H3,(H,16,17) Key: HJMQDJPMQIHLPB-UHFFFAOYSA-N;
	SMILES COC1=C(C=CC(=C1)C2=NNC(=O)C=C2)OC(F)F;
Properties
Chemical formula	C12H10F2N2O3
Molar mass	268.220 g·mol−1
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references

Zardaverine is a dual-selective PDE3/4 phosphodiesterase inhibitor.^[1] Studies in vitro suggest that it may have useful anti-cancer properties.^[2]

References

^ Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID 22891752.
^ Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi:10.1038/s43018-019-0018-6

This article about an organic compound is a stub. You can help Wikipedia by expanding it.

[1] Kümmerle, AE; Schmitt, M; Cardozo, SV; Lugnier, C; Villa, P; Lopes, AB; Romeiro, NC; Justiniano, H; Martins, MA; Fraga, CA; Bourguignon, JJ; Barreiro, EJ (2012). "Design, Synthesis, and Pharmacological Evaluation of N-Acylhydrazones and Novel Conformationally Constrained Compounds as Selective and Potent Orally Active Phosphodiesterase-4 Inhibitors". Journal of Medicinal Chemistry. 55 (17): 7525–45. doi:10.1021/jm300514y. PMID 22891752.

[2] Corsello SM, Nagari RT, Spangler RD, et al. Discovering the anticancer potential of non-oncology drugs by systematic viability profiling. Nature Cancer (2020). doi:10.1038/s43018-019-0018-6

[1]

[2]

v t e Phosphodiesterase inhibitors
PDE1	MMPX SCH-51866 Vinpocetine
PDE2	BAY 60-7550 Carbazeran EHNA Oxindole PDP
PDE3	Adibendan Amrinone (inamrinone) Anagrelide Benafentrine Bucladesine Carbazeran Cilostamide Cilostazol Enoximone Ensifentrine Imazodan KMUP-1 Meribendan Milrinone Olprinone Parogrelil Pimobendan Pumafentrine Quazinone RPL-554 Siguazodan Trequinsin Vesnarinone Zardaverine
PDE4	Apremilast Arofylline Atizoram Benafentrine Catramilast CC-1088 CDP-840 CGH-2466 Cilomilast Cipamfylline Crisaborole Denbutylline Difamilast Drotaverine Ensifentrine Etazolate Filaminast Glaucine HT-0712 ICI-63197 Indimilast Irsogladine Lavamilast Lirimilast Lotamilast Luteolin Mesembrenone Mesembrine Mesopram Oglemilast Piclamilast Pumafentrine Revamilast Ro 20-1724 Roflumilast Rolipram Ronomilast RPL-554 RS-25344 Tetomilast Tofimilast YM-976 Zardaverine
PDE5	Acetildenafil Aildenafil Avanafil Beminafil Benzamidenafil Dasantafil Icariin Gisadenafil Homosildenafil Lodenafil Mirodenafil MY-5445 Nitrosoprodenafil Norcarbodenafil SCH-51866 Sildenafil Sulfoaildenafil T-0156 Tadalafil Udenafil Vardenafil
PDE7	BRL-50481
PDE9	BAY 73-6691 PF-04447943 Paraxanthine
PDE10	Balipodect Mardepodect MK-8189 Papaverine TC-E 5005 Tofisopam
PDE11	BC11-38
Non-selective	Aminophylline Caffeine Choline theophyllinate CPX Dipyridamole Doxofylline Enprofylline Ibudilast IBMX Luteolin Pentoxifylline Propentofylline Theobromine Theophylline Zaprinast
Unsorted	Diazepam Diprophylline DPCPX Furafylline Lisofylline MDL-12330A Moxaverine Oxagrelate Pentifylline Proxyphylline Quercetin Satigrel Tolafentrine Trapidil
See also: Receptor/signaling modulators